Ad
related to: fda approved mek inhibitors- Sign Up for Updates
Sign up to stay in the know
about the latest information.
- Want to Know More?
Download this helpful guide
when considering pLGG treatments.
- Access Support Resources
Download support resources
for children like yours.
- See What to Expect
Download this guide for info
and results for this treatment.
- Sign Up for Updates
Search results
Results from the WOW.Com Content Network
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase enzymes MEK1 and/or MEK2. ... FDA-approved to treat BRAF-mutated melanoma.
Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5] Inappropriate activation of the pathway has been shown to occur in many cancers. [ 5 ] In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K ...
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. [2] [8] Cobimetinib is a MEK inhibitor. [2] ...
The specific compound is not approved by the FDA as a therapeutic agent, though it has been used in medical settings. [7] Members of this broad class of chemical compounds have been approved by the US FDA for the treatment of specific cancers. [8] [9] It is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase.
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [6] [7] It is a MEK inhibitor drug with anti-cancer activity. [8]
Selumetinib is a kinase inhibitor, more specifically a selective inhibitor of the enzyme mitogen-activated protein kinase kinase (MAPK kinase or MEK) subtypes 1 and 2. These enzymes are part of the MAPK/ERK pathway, which regulates cell proliferation (i.e., growth and division) and is overly active in many types of cancer. [18]
Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. 4 FDA-Approved ...
Further trials are planned including a trial of vemurafenib co-administered with GDC-0973 (cobimetinib), a MEK-inhibitor. [19] After good results in 2014, the combination was submitted to the European Medical Agency and the US Food and Drug Administration for marketing approval.
Ad
related to: fda approved mek inhibitors